
Aerpio Pharmaceuticals, Inc. ARPO
Aerpio Pharmaceuticals, Inc. Total Liabilities 2011-2026 | ARPO
Annual Total Liabilities Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 1.87 M | 3.4 M | 5.46 M | 3.59 M | 230 K | 205 K | 160 K | 133 K | 104 K | 74.8 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.46 M | 74.8 K | 1.52 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
845 M | $ 28.91 | 4.94 % | $ 1.4 B | ||
|
Amarin Corporation plc
AMRN
|
280 M | $ 15.03 | 1.14 % | $ 6.13 B | ||
|
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | ||
|
argenx SE
ARGX
|
704 M | $ 836.13 | 0.31 % | $ 25 B | ||
|
I-Mab
IMAB
|
707 M | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
8.95 M | $ 4.14 | 5.61 % | $ 353 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
38.7 M | $ 3.18 | 11.58 % | $ 179 M | ||
|
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | ||
|
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | ||
|
Aptorum Group Limited
APM
|
4.35 M | $ 0.78 | -8.44 % | $ 4.25 M | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
11.2 B | $ 198.18 | 1.37 % | $ 29 B | ||
|
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.47 | -1.12 % | $ 8.35 B | ||
|
Bristol-Myers Squibb Company
BMY
|
71.5 B | $ 60.84 | 1.64 % | $ 124 B | ||
|
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
3.12 B | $ 106.92 | 1.1 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
1.29 B | $ 217.6 | -0.23 % | $ 5 B | ||
|
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | ||
|
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
161 M | $ 40.32 | 5.15 % | $ 4.16 B | ||
|
CRISPR Therapeutics AG
CRSP
|
343 M | $ 53.56 | 9.46 % | $ 4.82 B | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B | ||
|
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.41 | 2.32 % | $ 360 M | ||
|
Burford Capital Limited
BUR
|
1.45 B | $ 9.35 | 0.54 % | $ 1.51 B | ||
|
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 14.93 | 2.02 % | $ 4.61 B | ||
|
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M |